Understand the source comparison
SS-31 Aging: Cardiolipin vs General Antioxidant Comparison
When evaluating SS-31 aging research against conventional mitochondrial support strategies, mechanism specificity determines efficacy. SS-31 (Elamipretide) Cardiolipin stabilization; prevents oxidative damage at inner mitochondrial membrane Selectively concent
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- When evaluating SS-31 aging research against conventional mitochondrial support strategies, mechanism specificity determines efficacy.
- SS-31 (Elamipretide)
- Cardiolipin stabilization; prevents oxidative damage at inner mitochondrial membrane
- Selectively concentrates in inner membrane via membrane potential gradient
- Preclinical: restored cristae structure, improved ATP synthesis, enhanced mitochondrial quality control in aged rodents
- Most mechanistically targeted approach. Addresses root cause of mitochondrial aging rather than downstream oxidative stress
- CoQ10 / Ubiquinol
- Electron carrier in respiratory chain; lipid-phase antioxidant
- Limited. Requires active uptake and faces bioavailability challenges at therapeutic doses
- Mixed clinical results; benefits most pronounced in CoQ10 deficiency states, minimal evidence for age reversal in healthy aging
- Supports existing respiratory function but doesn't repair membrane damage or restore cristae architecture
- MitoQ / SkQ1
- Mitochondria-targeted antioxidants (CoQ10 conjugated to lipophilic cation)
- Moderate. Triphenylphosphonium cation drives mitochondrial accumulation
- Preclinical models show reduced oxidative damage markers; human trials show modest improvements in vascular function in older adults
- Scavenges ROS after generation but doesn't prevent electron leak at the source; less specific than cardiolipin binding
- NAD+ Precursors (NMN/NR)
- Boosts NAD+ levels to support sirtuins, PARP enzymes, and mitochondrial biogenesis
- Indirect. Enhances mitochondrial biogenesis but doesn't repair existing damaged mitochondria
- Human trials show increased NAD+ levels; evidence for functional improvement in aging is preliminary and inconsistent
- Increases mitochondrial quantity but doesn't improve quality of existing dysfunctional mitochondria
- Rapamycin / mTOR Inhibitors
- Induces autophagy/mitophagy; removes damaged mitochondria
- Indirect. Promotes clearance of damaged mitochondria rather than repair
- Robust lifespan extension in model organisms; human trials ongoing; side effect profile requires careful monitoring
- Addresses mitochondrial aging through clearance rather than stabilization; complementary rather than competitive with SS-31
- SS-31 occupies a unique position because it's the only intervention designed to preserve the physical structure of the inner mitochondrial membrane where age-related damage accumulates fastest. Most mitochondrial supplements increase substrate availability or antioxidant capacity, but cardiolipin oxidation continues unchecked. Research comparing SS-31 directly to MitoQ in aged mouse models found that while both reduced oxidative stress markers, only SS-31 restored cristae density and respiratory supercomplex formation. The structural prerequisites for efficient ATP synthesis.